Blueprint Medicines Corporation

NasdaqGS:BPMC Stock Report

Market Cap: US$6.5b

Blueprint Medicines Management

Management criteria checks 2/4

Blueprint Medicines' CEO is Kate Haviland, appointed in Apr 2022, has a tenure of 3.08 years. total yearly compensation is $13.48M, comprised of 6.1% salary and 93.9% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $7.10M. The average tenure of the management team and the board of directors is 4.8 years and 10 years respectively.

Key information

Kate Haviland

Chief executive officer

US$13.5m

Total compensation

CEO salary percentage6.09%
CEO tenure3.1yrs
CEO ownership0.1%
Management average tenure4.8yrs
Board average tenure10yrs

Recent management updates

Recent updates

There's Reason For Concern Over Blueprint Medicines Corporation's (NASDAQ:BPMC) Massive 28% Price Jump

May 04
There's Reason For Concern Over Blueprint Medicines Corporation's (NASDAQ:BPMC) Massive 28% Price Jump

Blueprint Medicines: Strong Business, Ambitious Targets, Expensive Stock

Mar 29

Is Blueprint Medicines (NASDAQ:BPMC) A Risky Investment?

Mar 07
Is Blueprint Medicines (NASDAQ:BPMC) A Risky Investment?

Revenues Not Telling The Story For Blueprint Medicines Corporation (NASDAQ:BPMC) After Shares Rise 28%

Jan 24
Revenues Not Telling The Story For Blueprint Medicines Corporation (NASDAQ:BPMC) After Shares Rise 28%

Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Nov 24
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?

Blueprint Medicines: Growth For The Long Term Still Mostly Priced In

Sep 27

Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Aug 16
Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?

Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Jul 23
Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S

Blueprint Medicines: Overdue For A Breather

Jul 16

Blueprint Medicines: Rampant Growth Mostly Priced In

May 04

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

Feb 20

CEO Compensation Analysis

How has Kate Haviland's remuneration changed compared to Blueprint Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$156m

Dec 31 2024US$13mUS$821k

-US$67m

Sep 30 2024n/an/a

-US$128m

Jun 30 2024n/an/a

-US$205m

Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$6mUS$782k

-US$507m

Sep 30 2023n/an/a

-US$555m

Jun 30 2023n/an/a

-US$554m

Mar 31 2023n/an/a

-US$581m

Dec 31 2022US$6mUS$701k

-US$558m

Sep 30 2022n/an/a

-US$718m

Jun 30 2022n/an/a

-US$702m

Mar 31 2022n/an/a

-US$650m

Dec 31 2021US$4mUS$501k

-US$644m

Sep 30 2021n/an/a

-US$411m

Jun 30 2021n/an/a

US$340m

Mar 31 2021n/an/a

US$325m

Dec 31 2020US$2mUS$461k

US$314m

Sep 30 2020n/an/a

US$333m

Jun 30 2020n/an/a

-US$395m

Mar 31 2020n/an/a

-US$371m

Dec 31 2019US$3mUS$432k

-US$348m

Sep 30 2019n/an/a

-US$362m

Jun 30 2019n/an/a

-US$340m

Mar 31 2019n/an/a

-US$267m

Dec 31 2018US$3mUS$393k

-US$237m

Compensation vs Market: Kate's total compensation ($USD13.48M) is above average for companies of similar size in the US market ($USD8.66M).

Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.

CEO

Kate Haviland (48 yo)

3.1yrs
Tenure
US$13,477,004
Compensation

Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...

Leadership Team

NamePositionTenureCompensationOwnership
Kathryn Haviland
President3.1yrsUS$13.48m0.11%
$ 7.1m
Alexis Borisy
Co-Founder & Directorno dataUS$549.69k0.11%
$ 7.2m
Michael Landsittel
Chief Financial Officer9.3yrsUS$4.19m0.067%
$ 4.3m
Christina Rossi
Chief Operating Officer3.1yrsUS$6.54m0.030%
$ 1.9m
Percy Carter
Chief Scientific Officer4yrsUS$5.13m0.030%
$ 1.9m
Fouad Namouni
President of Research & Development4.7yrsUS$5.50m0.049%
$ 3.2m
Ariel Hurley
Senior Vice President of Finance and Principal Accounting Officerno datano data0.026%
$ 1.7m
Jenna Cohen
Senior Director & Head of Investor Relationsno datano datano data
Tracey McCain
Executive VP8.7yrsUS$2.34m0.057%
$ 3.7m
Debra Durso-Bumpus
Chief People Officer5.3yrsno data0.036%
$ 2.3m
Julian Baker
Senior Vice President of Corporate Affairsno datano datano data
Becker Hewes
Chief Medical Officer5yrsno data0.047%
$ 3.1m
4.8yrs
Average Tenure
53yo
Average Age

Experienced Management: BPMC's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Kathryn Haviland
President3.1yrsUS$13.48m0.11%
$ 7.1m
Alexis Borisy
Co-Founder & Director14.1yrsUS$549.69k0.11%
$ 7.2m
George Demetri
Chair of Scientific Advisory Board13yrsUS$333.38kno data
Lynn Seely
Lead Independent Director9.1yrsUS$606.19k0.017%
$ 1.1m
Charles Sawyers
Member of Scientific Advisory Boardno datano datano data
Brian Druker
Member of Scientific Advisory Boardno datano datano data
Nicholas Lydon
Member of Scientific Advisory Board & Independent Director14.1yrsUS$569.69k0.086%
$ 5.6m
Lonnel Coats
Independent Director9.3yrsUS$572.59k0%
$ 0
William Hahn
Member of Scientific Advisory Boardno datano datano data
Scott Lowe
Member of Scientific Advisory Boardno datano datano data
Daniella Beckman
Independent Director3.4yrsUS$574.69k0.012%
$ 749.1k
Jeffrey Albers
Chairman of the Board of Director10.8yrsUS$586.19k0.22%
$ 14.3m
10.0yrs
Average Tenure
62yo
Average Age

Experienced Board: BPMC's board of directors are seasoned and experienced ( 10 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 19:48
End of Day Share Price 2025/05/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blueprint Medicines Corporation is covered by 36 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Ishan MajumdarBaptista Research
Peter LawsonBarclays